AbbVie Inc. is 30.1x more valuable than BridgeBio Pharma, Inc. by market capitalization ($397.44 B vs $13.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BBIO | ABBV |
|---|---|---|
| Market cap | $13.20 B | $397.44 B |
| US-listed rank | #791 | #28 |
| Revenue (latest FY) | $502.08M | $61.16B |
| Net income (latest FY) | - | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 777 | 1,008 |
AbbVie Inc. is 30.1x more valuable than BridgeBio Pharma, Inc. by market capitalization ($397.44 B vs $13.20 B).
In their latest fiscal years, BridgeBio Pharma, Inc. reported $502.08M in revenue while AbbVie Inc. reported $61.16B.
Full pages: BridgeBio Pharma, Inc. and AbbVie Inc., or browse the full rankings.